# A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).

> **NCT06551818** · NA · NOT_YET_RECRUITING · sponsor: **NovoBliss Research Pvt Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Androgenic Alopecia

## Interventions

- **OTHER:** SesZen-Bio Low Dose 1 (350 mg extract)
- **OTHER:** SesZen-Bio Low Dose 1 (150 mg liposomal)
- **OTHER:** SesZen-Bio High Dose 1 (500 mg extract)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06551818
- **Lead sponsor:** NovoBliss Research Pvt Ltd
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2025-03-02
- **Final completion:** 2025-03-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551818, "A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06551818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*